NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-20-061 from the NIH Guide for Grants and Contracts. This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be given to investigations of co-infections with known oncogenic agents (e.g., Helicobacter pylori [H. pylori] and Epstein Barr virus [EBV]; excluding human immunodeficiency virus [HIV]) and of co-infections that engendered novel opportunities for prevention and treatment. Coinfection is defined as the occurrence of infections by two or more infectious (pathogenic or nonpathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms.
Funding Opportunity PAR-20-062 from the NIH Guide for Grants and Contracts. This initiative seeks to enhance our mechanistic and epidemiologic understanding of infection-related cancers, with a focus on the etiologic roles of co-infection in cancer. Preference will be given to investigations of co-infections with known oncogenic agents (e.g., Helicobacter pylori [H. pylori] and Epstein Barr virus [EBV]; excluding human immunodeficiency virus [HIV]) and of co-infections that engendered novel opportunities for prevention and treatment. Coinfection is defined as the occurrence of infections by two or more infectious (pathogenic or nonpathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms.
Notice NOT-OD-20-031 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-026 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-016 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-19-017 from the NIH Guide for Grants and Contracts. Following intentional weight loss, physiological processes including altered appetite and decreased energy expenditure create a tendency toward regain of lost weight. This Funding Opportunity Announcement (FOA) invites UG3/UH3 cooperative agreement applications from multi-disciplinary teams that propose to conduct collaborative mechanistic clinical trials focused on elucidation of the physiological mechanisms underlying individual variability in maintenance of reduced weight over time. This FOA will not support studies with a goal to evaluate the efficacy of interventions for weight loss or maintenance of reduced weight. Participants must be studied before and after a successful behavioral/lifestyle weight loss intervention to determine the extent, durability, and mechanisms for physiologic adaptations to weight loss, including metabolic and biobehavioral mechanisms. It is expected that tissue biospecimens will be collected that can be used to identify potential metabolic pathways that are altered after weight loss and may render it more difficult to maintain the reduced weight. This Funding Opportunity Announcement (FOA) will use the bi-phasic, milestone-driven UG3/UH3 cooperative agreement mechanism in parallel with a companion FOA, RFA DK-19-018, Physiology of the Weight Reduced State Data Coordinating Center (U24 Clinical Trial Not Allowed). Awards made under this FOA will initially support a planning/preparation phase (UG3) for approximately one year with possible transition to a study (UH3) phase of up to four additional years once planning milestones are met. Applications submitted in response to this FOA must propose activities for both phases and are expected to include plans for project management and performance milestones for each phase.
The Physiology of the Weight Reduced State Data Coordinating Center (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-19-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U24 cooperative agreement applications for a Data Coordination Center to participate in a clinical trial focused on elucidation of the physiological mechanisms underlying individual variability in maintenance of reduced weight over time. A companion FOA (RFA DK-19-017, The Physiology of the Weight Reduced State Clinical Trial Consortium (UG3/UH3 Clinical Trial Required) invites Clinical Centers (CC) to recruit and study participants before and after a behavioral/lifestyle weight loss intervention to determine the extent, durability and mechanisms for physiologic adaptations to weight loss, including metabolic and biobehavioral mechanisms. It is expected that tissue biospecimens will be collected that can be used to identify potential metabolic pathways that are altered after weight loss and may render it more difficult to maintain the reduced weight. An award made under the current FOA will support a planning/preparation phase for approximately one year, followed by a study phase of up to four additional years once planning milestones are met. Applications submitted in response to this FOA must propose activities for both phases and are expected to include plans for project management and performance milestones for each phase.
Funding Opportunity PAR-20-063 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.
Funding Opportunity RFA-MH-20-351 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this FOA.
Funding Opportunity RFA-MH-20-350 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this FOA.
Notice NOT-OD-20-019 from the NIH Guide for Grants and Contracts
Notice NOT-AI-20-011 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-013 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-OH-20-003 from the NIH Guide for Grants and Contracts. The purpose of this announcement intended to provide funding to municipalities, port authorities, other appropriate public entities, not-for-profit organizations, and other qualified persons to conduct commercial fishing vessel safety training for vessel operators and crewmembers.
Funding Opportunity RFA-OH-20-002 from the NIH Guide for Grants and Contracts. The purpose of this is intended to provide funding to individuals in academia, members of non-profit organizations and businesses involved in fishing and maritime matters, and other entities with expertise in commercial fishing safety.
Notice NOT-HL-19-729 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-20-012 from the NIH Guide for Grants and Contracts. This initiative will provide two years of support for planning activities necessary for initiating a Phase III clinical trial designed to validate VCID biomarkers and/or treat patients with VCID. The full spectrum of VCID is in scope, and the one or more VCID disorders(s) to be targeted in the trial must be clearly specified in the application, for example (but not limited to): vascular insults including clinical stroke, silent infarcts and microinfarcts, leukoaraiosis, cerebral amyloid angiopathy (CAA), transient ischemic attack (TIA), micro-bleeds, CADASIL, and vascular contributions to Alzheimers dementia. Planning activities may include identifying trial sites/collaborations, designing trial protocols and procedures, and addressing regulatory approvals.
Addressing Suicide Research Gaps: Understanding Mortality Outcomes (R01 Clinical Trial Not Allowed )
Funding Opportunity RFA-MH-20-305 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to leverage data from existing basic, clinical, and intervention research on suicide risk and behaviors as well as social media and healthcare records data, by encouraging the integration of existing data sets for novel secondary analyses aimed at identifying potential biological, experiential, and other predictors and moderators of suicide risk. The use of dimensional variables and inclusion of multiple levels of analyses is particularly encouraged.
Funding Opportunity RFA-MH-20-307 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to support efforts focused on linking pertinent data from healthcare system records (e.g., suicide attempt events) to mortality data so that a more accurate understanding of the risk factors for, and the burden of, suicide among those seen in structured healthcare settings can be discerned.
Notice NOT-CA-20-006 from the NIH Guide for Grants and Contracts